Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 000-55000

EARTH SCIENCE TECH, INC.

(Exact name of registrant as specified in its charter)

Florida

80-0931484

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

8950 SW 74^th CT

Suite 1401

Miami, FL 33156

(Address of principal executive offices) (zip code)

(305) 724-5684

(Registrant’s telephone number, including area code)

8950 SW 74^th CT

Suite 101

Miami, FL 33156, USA

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock $0.001 par value		ETST		Over the Counter Bulletin Board

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large, accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large, accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of September 30, 2024, there were 303,635,893 Common and 1,000,000 Preferred shares of the registrant’s stock outstanding.

TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION

ITEM 1.	Financial Statements (Unaudited)	F-1
	Consolidated Balance Sheets	F-1
	Consolidated Statements of Operations	F-2
	Consolidated Statements of Changes in Shareholders’ Equity	F-3
	Consolidated Statements of Cash Flows	F-4
	Notes to Consolidated Financial Statements	F-5- F-16
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3
ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	8
ITEM 4.	Controls and Procedures	8

PART II. OTHER INFORMATION

ITEM 1.	Legal Proceedings	9
ITEM 1A.	Risk Factors	9
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	9
ITEM 3.	Defaults Upon Senior Securities	9
ITEM 4.	Mine Safety Disclosures	9
ITEM 5.	Other Information	9
ITEM 6.	Exhibits	9

SIGNATURES		10

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

EARTH SCIENCE TECH, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	As of September 30, 2024			As of March 31, 2024
	(Unaudited)			(Audited)
ASSETS
Current Assets:
Cash	$	1,532,211		$	697,721
Accounts Receivable		203,942			235,423
Deposits		22,608			9,352
Inventory		432,217			315,738
Prepaid		90,110			—
Total current assets		2,281,088			1,258,234

Non-Current Assets:
Property and Equipment, net		216,346			135,352
Right of use asset, net		219,627			156,517
Goodwill		2,302,792			2,302,792
Intangible Assets, net		29,775			28,441
Total Assets	$	5,049,628		$	3,881,336

LIABILITIES AND EQUITY
Accounts payable	$	392,227		$	530,724
Accrued expenses and other payable		1,158,238			854,719
Current portion of operating lease obligations		118,227			70,487
Current portion of loans and obligations		30,592			30,592
Total Current Liabilities		1,699,284			1,486,522

Long-Term Liabilities:
Lease liability less current maturities		100,690			84,950
Equipment loans and obligations non-current		48,522			60,559
Total Liabilities		1,848,496			1,632,031
Commitment and Contingencies ( Note 12)		-			-
Stockholders’ Equity:
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 0 shares issued and outstanding as of September 30, 2024, and March 31, 2024, respectively		1,000			1,000
Common stock, par value $0.001 per share, 350,000,000 shares authorized; 303,635,923 and 309,981,819 shares issued and outstanding as of September 30, 2024, and March 31, 2024 respectively		303,636			309,982
Additional paid-in capital		30,676,950			31,593,399
Accumulated deficit		(27,780,454	)		(29,655,076	)
Total stockholders’ Equity		3,201,132			2,249,305
Total Liabilities and Equity	$	5,049,628		$	3,881,336

The accompanying condensed notes are an integral part of these unaudited consolidated financial statements.

F-1

EARTH SCIENCE TECH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2024, AND 2023.

(UNAUDITED)

	2024			2023			2024			2023
	For the Three Months Ended September 30,						For the Six Months Ended September 30,
	2024			2023			2024			2023
				(As restated)						(As restated)
Revenue	$	8,519,047		$	1,927,720		$	17,087,965		$	2,147,654
Cost of Goods Sold (exclusive of depreciation shown separately below)		2,252,366			746,226			4,410,850			817,391
Gross Profit		6,266,681			1,181,494			12,677,115			1,330,263

Expenses:
Salaries Expense		3,605,954			193,917			6,941,084			258,305
General and Administrative Expense		1,259,422			93,962			2,580,405			161,462
Bank Charges		271,452			—			560,297			—
Marketing		152,520			5,148			363,966			16,524
Legal and Professional Fees		63,259			407,626			181,706			424,546
Insurance Expense		45,021			—			80,826			—
Depreciation and Amortization		33,191			1,097			63,423			64,093
Utilities		6,302			—			10,830			—
Total Expenses		5,437,121			701,750			10,782,537			924,930
Net Operating Income		829,560			479,944			1,894,578			405,333

Other Income/Expenses
Other Income					(452	)		13,200			(452	)
Interest expense		(2,843	)	$	(34,911	)		(4,807	)	$	(47,509	)
Net Income before taxes		826,717			444,581			1,902,971			357,372

Income Taxes		28,349						28,349			—

Net Income	$	798,368		$	444,581		$	1,874,622		$	357,372
Profit/(Loss) per common share-Basic and Diluted	$	0.003		$	0.001		$	0.006		$	0.001
Weighted average number of common shares outstanding		306,047,031			314,881,821			307,989,312			314,881,821

The accompanying condensed notes are an integral part of these unaudited consolidated financial statements.

F-2

EARTH SCIENCE TECH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

For the six months ended September 30, 2024


	Common Stock						Preferred Stock				Additional Paid-in			Accumulated
Description	Shares			Amount			Shares		Amount		Capital			Deficit			Total
Balance at March 31, 2024		309,981,819			309,982			1,000,000		1,000		31,593,399			(29,655,076	)	$	2,249,305
Common stock buyback		(6,345,896	)		(6,346	)		—		—		(916,449	)		—		$	(922,795	)
Net Income					-					-		-			1,874,622		$	1,874,622
Balance at September 30, 2024		303,635,923		$	303,636			1,000,000	$	1,000	$	30,676,950		$	(27,780,454	)	$	3,201,132

For the three months ended September 30, 2024


	Common Stock						Preferred Stock				Additional Paid-in			Accumulated
Description	Shares			Amount			Shares		Amount		Capital			Deficit			Total
Balance at June 30, 2024		309,067,711			309,068			1,000,000		1,000		31,435,840			(28,578,822	)	$	3,167,086
Common stock buyback		(5,431,788	)		(5,432	)		—		—		(758,890	)		—		$	(764,322	)
Net Income					-					-		-			798,368		$	798,368
Balance at September 30, 2024		303,635,923		$	303,636			1,000,000	$	1,000	$	30,676,950		$	(27,780,454	)	$	3,201,132

For the six months ended September 30, 2023


	Common Stock				Preferred Stock				Additional Paid-in		Accumulated
	Shares		Amount		Shares		Amount		Capital		Deficit			Total
Balance at March 31, 2023 (As restated)		282,611,083		282,612		1,000,000		1,000		31,303,138		(30,467,214	)		1,119,535

Common stock issued for cash		18,533,334		18,534						91,467					110,001
Common stock issued for conversion of note payable		13,406,313		13,406						371,594					385,000
Net Profit/(Loss)		—		—		—		—		—		357,372			357,372
Balance at September 30, 2023 (As restated) Note 3		314,550,730	$	314,552		1,000,000	$	1,000	$	31,766,199	$	(30,109,842	)	$	1,971,909

For the three months ended September 30, 2023


	Common Stock				Preferred Stock				Additional Paid-in		Accumulated
Description	Shares		Amount		Shares		Amount		Capital		Deficit			Total
Balance at June 30, 2023 (As restated) Note 3		314,550,730		314,552		1,000,000		1,000		31,766,199		(30,554,423	)	$	1,527,328
Balance		314,550,730		314,552		1,000,000		1,000		31,766,199		(30,554,423	)	$	1,527,328
Net Income (Loss)		—		—		—		—		—		444,581		$	444,581
Balance at September 30, 2023 (As restated) Note 3		314,550,730	$	314,552		1,000,000	$	1,000	$	31,766,199	$	(30,109,842	)	$	1,971,909
Balance		314,550,730	$	314,552		1,000,000	$	1,000	$	31,766,199	$	(30,109,842	)	$	1,971,909

The accompanying condensed notes are an integral part of these unaudited consolidated financial statements.

F-3

EARTH SCIENCE TECH, INC. AND SUBSIDIARIES

STATEMENTS OF CASH FLOWS

FOR SIX MONTHS ENDED SEPTEMBER 30, 2024, AND 2023.

(UNAUDITED)

	2024			2023 (As restated)
Cash flows from operating activities:
Net Income	$	1,874,622		$	357,372
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		63,423			64,093

Changes in operating assets and liabilities:
Accounts Receivable		31,481			(62,860	)
Deposits		(13,256	)		—
Prepaid expenses and other current assets		(90,110	)		—
Inventory		(116,478	)		(200,980	)
Other current liabilities		—			28,000
Lease Liability, net		(36,814	)		(34,094	)
Accrued settlement		—			(185,947	)
Accounts payable and accrued expenses		165,049			162,326
Net cash provided in operating activities		1,877,917			127,910

Cash flows from investing activities:
Purchases of property and equipment and intangibles		(108,595	)		—
Net cash used in investing activities		(108,595	)		—

Cash flows from financing activities:
Proceeds from issuance of common stock		—			110,001
Payments on debt obligations		(12,037	)		(86,017	)
Repurchase of common stock		(922,795	)		—
Net Cash provided by (used) in financing activities		(934,832	)		23,984
Net increase in cash and cash equivalents		834,490			151,894
Cash and cash equivalents at beginning of the period		697,721			35,756
Cash and cash equivalents at end of the period	$	1,532,211		$	187,650

Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	$	4,807			—
Cash paid for income taxes	$	28,349

Non-Cash Transactions
Initial recognition of right of use asset	$	100,294		$	-
Common stock issued on conversion of notes payable	$	—		$	385,000

The accompanying condensed notes are an integral part of these unaudited consolidated financial statements.

F-4

EARTH SCIENCE TECH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024

(UNAUDITED)

Note 1 — Organization and Nature of Operations

Earth Science Tech, Inc. (“ETST” or the “Company”) was incorporated under the laws of the State of Nevada on April 23, 2010. The Company subsequently changed its domicile to the State of Florida on June 27, 2022. As of November 8, 2022, the Company is a holding entity set to acquire companies with its current focus in the health and wellness industry. The Company is presently in compounding pharmaceuticals and telemedicine through its wholly owned subsidiaries RxCompoundStore.com, LLC. (“RxCompound”), Peaks Curative, LLC. (“Peaks”), and Earth Science Foundation, Inc. (“ESF”).

RxCompound is a complete compounding pharmacy. RxCompound is currently licensed to fulfill prescriptions in 22 states: Delaware, Florida, Pennsylvania, New York, Arizona, New Jersey, Wisconsin, Minnesota, Rhode Island, Utah, Georgia, Nevada, Massachusetts, Missouri, Iowa, Maryland, Ohio, Colorado, North Carolina, Maine, Indiana and Illinois. RxCompound is in the application process to obtain licenses in the remaining states in which it is not yet licensed to fulfill prescriptions.

Peaks is a telemedicine referral site focused on overall health and wellness for men and women. Peaks’ orders are exclusively fulfilled by RxCompound. Patients who order Peaks via monthly subscription receive their refills automatically. The company intends to expand offerings to include over the counter (“OTC”) (non-prescription) products such as supplements and topicals.

ESF is a favored entity of ETST, effectively being a non-profit organization that was incorporated on February 11, 2019, and is structured to accept grants and donations to help those in need of assistance in paying for prescriptions.

These financial statements should be read in conjunction with audited consolidated financial statements and notes.

Note 2 — Summary of Significant Accounting Policies

Basis of presentation

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).

These financial statements must be read in conjunction with audited consolidated financial statements and notes thereto which are included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 for a broader discussion of the Company’s business and risks inherent in such business. In the opinion of management, all adjustments considered for a fair presentation, consisting solely of normal and recurring adjustments have been made. The results of operations for the three and six months ended September 30, 2024, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending March 31, 2025.

Principles of consolidation

The accompanying consolidated financial statements include all the accounts of the Company and its wholly owned subsidiaries RxCompound, Peaks and ESF. All intercompany transactions have been eliminated during consolidation.

F-5

Use of estimates and assumptions

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas requiring significant estimates are impairment of goodwill, provision for taxation, accrued liabilities, liabilities for legal matters, the determination of useful lives of depreciable and intangible assets, contingencies, and going concern assessment. The estimates and underlying assumptions are reviewed on an ongoing basis. Actual results could differ from those estimates.

Carrying value, recoverability, and impairment of long-lived assets

The Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable through the estimated undiscounted cash flows expected to result from the use and eventual disposition of the assets. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value. As of September 30, 2024, and 2023 no such impairment was needed.

Cash and cash equivalents

Cash and cash equivalents include all highly liquid debt instruments with original maturities of three months or less which are not securing any corporate obligations. As of September 30, 2024, and March 31,2024, the Company held a cash balance of $1,532,211, and $697,721, respectively, the organization’s balances exceeded federally insured limits by approximately $1,282,211 as of September 30, 2024, and $266,090 as of March 31, 2024.

Accounts Receivable.

The Company has adopted the new standard ASC-326- CECL to account for current credit losses. The Company has analyzed its accounts receivable, based on historical and customer experience, economic trends, and future estimates. Accounts receivable are recorded for pharmaceuticals picked up or shipped as of September 30, 2024, and March 31, 2024. Accounts receivables are expected to be collected within twelve months in its entirety, therefore no reserve was necessary.

Schedule of Accounts Receivable


	As of
	September 30, 2024		March 31, 2024
Accounts Receivable	$	203,942	$	235,423

F-6

Revenue recognition

The Company has implemented ASC 606, Revenue from Contracts with Customers for revenue recognition by incorporating the necessary changes in systems and processes. These changes included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures. Revenue is recognized at this point in time.

The Company recognizes revenue from product sales or services rendered when control of the promised goods is transferred to our customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenue when or as the Company satisfies a performance obligation.

Disaggregated Revenue

The Company disaggregates revenue from contracts with customers by category — core and non-core, as it believes it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

The Company’s disaggregated revenue by category is as follows:

Schedule of Disaggregated Revenue


	For the six months ended September 30,
	2024		2023
Core:
Sale of Pharmaceutical products – RxCompound and Peaks	$	16,563,906	$	2,147,654
Total core revenue, net	$	16,563,906	$	2,147,654
Non-Core:
Shipping Income	$	524,059	$	—
Total revenue, net	$	17,087,965	$	2,147,654

The Company currently has three large customers, each representing 14%, 12% and 9% of revenue for the six months ended September 30, 2024.

Inventory

The Company has its inventories stated at a lower cost (on first in, first out (FIFO) method) or market value basis. A reserve is established if necessary to reduce excess or obsolete inventories to their realizable value. The stated cost consists of finished products. Reserves, if necessary, are recorded to reduce inventory to market value based on assumptions about consumer demand, current inventory levels and product life cycles for the various inventory items. These assumptions are evaluated annually and are based on the Company’s business plan and on feedback from customers and the product development team. As of September 30, 2024, and March 31, 2024, the inventory reserves were not material. The Company has three main suppliers, that account for 28%, 12% and 8% of the company’s vendor purchases.

Cost of Goods Sold

Components of cost of goods sold include product costs, consumables, shipping costs to customers and any inventory adjustments.

F-7

Shipping and Handling Costs

Costs incurred by the Company for shipping and handling are included in costs of revenues.

Related parties

The Company pays the employee compensation for Giorgio R. Saumat and Mario Tabraue to their respective, solely owned LLCs, Point96 Consulting, LLC and Tabraue Consulting, LLC.

The Company follows ASC 850-10, Related Parties, for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20, the related parties include: (a) affiliates of the Company (“Affiliate” means, with respect to any specified person, any other person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such person, as such terms are used in and construed under Rule 405 under the Securities Act); (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the Company; (e) management of the Company; (f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

Income taxes

The Company accounts for income taxes under ASC 740, Income Taxes. Under ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period, which includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

F-8

Net income per common share

The Company follows ASC 260 to account for earnings per share. Basic earnings per common share calculations are determined by dividing net results from operations by the weighted average number of shares of common stock outstanding during the year. Diluted loss per common share calculation is determined by dividing net results from operations by the weighted average number of common shares and diluted common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation, for the three and six months ended September 30, 2024 and 2023, the Company did not have any antidilutive equity instruments.

Cash flows reporting

The Company follows ASC 230 to report cash flows. This standard classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by this standard to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments. The Company reports separately information about investing and financing activities not resulting in cash receipts or payments in the period pursuant to this standard.

Goodwill

Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a purchase business combination. Goodwill is reviewed for impairment on an annual basis, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may be impaired. In conducting its annual impairment test, the Company first reviews qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If factors indicate that the fair value of the reporting unit is less than its carrying amount, the Company performs a quantitative assessment, and the fair value of the reporting unit is determined by analyzing the expected present value of future cash flows. If the carrying value of the reporting unit continues to exceed its fair value, the fair value of the reporting unit’s goodwill is calculated and an impairment loss equal to the excess is recorded.

Stock based compensation

The Company applies the fair value method of ASC 718, Compensation-Stock Compensation, in accounting for its stock-based compensation. These standards state that compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period, if any. The Company uses the Black-Scholes option pricing model to determine the fair value of its stock, stock option and warrant issuance. The determination of the fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price, as well as assumptions regarding a few complex and subjective variables. These variables include the Company’s expected stock price, volatility over the term of the awards, actual employee exercise behaviors, risk-free interest rate and expected dividends. The company has no stock-based commitments outstanding as of September 30, 2024, and March 31, 2024.

Fair Value

FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) establishes a framework for all fair value measurements and expands disclosures related to fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories:

Level 1 — Quoted market prices for identical assets or liabilities in active markets or observable inputs; and

F-9

Level 2 — Significant other observable inputs that can be corroborated by observable market data; and

Level 3 — Significant unobservable inputs that cannot be corroborated by observable market data.

The carrying amounts of cash, accounts payable and other liabilities, accrued expenses and settlement payable approximate fair value because of the short-term nature of these items.

The fair value of the Company’s debt approximated the carrying value of the Company’s debt as of September 30, 2024, and September 30, 2023. Factors that the Company considered when estimating the fair value of its debt included market conditions, liquidity levels in the private placement market, variability in pricing from multiple lenders and terms of debt.

Property and equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. During the three months ended September 30, 2024, RxCompound added various equipment for its operations. Depreciation on equipment is charged using a straight-line method over the estimated useful life of 5 years.

Recently issued accounting pronouncements

We have considered the impact of the following pronouncements:

The FASB recently issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, which requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities for fiscal years beginning after December 15, 2021, with early adoption permitted (for an “emerging growth company,” beginning after December 15, 2023). The Company has assessed the impact this standard will have on the Company’s consolidated financial statements. No material adjustments were required.

F-10

Intangible Assets

Intangible assets consist of Peaks telemedicine platform, and the Holding Company’s web domains. Intangible assets with finite lives are amortized over the estimated useful life of five years.

Note 3 – Restatement

As of September 30, 2023, the Company’s subsidiary RXCompound carried a goodwill in the amount of $138,312, and it was included in intangible assets, and amortized, such amortization is being reversed, and the below set forth tables reflect the effect in the Company’s Consolidated Balance Sheet, Consolidated Statement of Stockholders’ Equity, and Consolidated Statement of Operations.

Schedule of Effect of Restatement

Adjustments to Consolidated Balance Sheet as of September 30, 2023

Consolidated Balance Sheet


	As of September 30, 2023
	September 30, 2023, before restatement		Restatement		September 30,2023 after restatement
Total Assets	$	3,041,344	$	38,269	$	3,079,613
Total stockholders’ Equity		1,933,640		38,269		1,971,909

Adjustments to Consolidated Statement of Stockholders’ Equity for the six months ended September 30, 2023

Consolidated Statement of Stockholders’ Equity


	For the six months ended September 30, 2023
	September 30, 2023, before restatement			Restatement		September 30, 2023, after restatement
Accumulated deficit	$	(30,148,111	)	$	38,269	$	(30,109,842	)
Stockholders’ Equity		1,933,640			38,269		1,971,909

F-11

Adjustments to Consolidated Statement of Operations for the six months ended September 30, 2023

Consolidated Statement of Operations


	For the six months ended September 30, 2023
	September 30, 2023, before restatement		Restatement			September 30, 2023, after restatement
Net Income	$	354,872	$	(2,500	)	$	357,372

Note 4 - Inventory

Schedule of Inventory


	As of
	September 30, 2024		March 31, 2024
Raw materials	$	334,312		266,776
Finished goods		97,905		48,962
Inventory	$	432,217	$	315,738

Note 5 — Property and Equipment

Schedule of Property and Equipment


	As of
	September 30, 2024			March 31, 2024
Equipment – cost	$	280,197		$	176,602
Less: Accumulated depreciation		(63,851	)		(41,250	)
Property and Equipment, Net	$	216,346		$	135,352

Depreciation expense for the six months ended September 30, 2024, and September 30, 2023, was $22,601 and $14,370, respectively.

Note 6 — Leases

The Company signed a new 2 -year lease agreement for additional office space located at 8950 SW 74^th CT, Miami FL 33156, suite 1401, The lease commencement date is September 15, 2024, with a base monthly rent of $4,078.12.

The Company treats a contract as a lease when the contract conveys the right to use a physically distinct asset for a period in exchange for consideration, or the Company directs the use of the asset and obtains substantially all the economic benefits of the asset. These leases are recorded as right-of-use (“ROU”) assets and lease obligation liabilities for leases with terms greater than 12 months. ROU assets represent the Company’s right to use an underlying asset for the entirety of the lease term. Lease liabilities represent the Company’s obligation to make payments over the life of the lease. A ROU asset and a lease liability are recognized at commencement of the lease based on the present value of the lease payments over the life of the lease. Initial direct costs are included as part of the ROU asset upon commencement of the lease. Since the interest rate implicit in a lease is generally not readily determinable for the operating leases, the Company uses an incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate represents the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar lease term to obtain an asset of similar value.

F-12

The Company reviews the impairment of ROU assets consistent with the approach applied for the Company’s other long-lived assets. The Company reviews the recoverability of long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations. The Company elected the practical expedient to exclude short-term leases (leases with original terms of 12 months or less) from ROU asset and lease liability accounts.

Supplemental balance sheet information related to leases were as follows:


	As of
	September 30, 2024		March 31, 2024
Assets
Right of use asset, net	$	219,627	$	156,517

Operating lease liabilities
Current		118,227		70,487
Non-current		100,690		84,950
Total Lease Liabilities	$	218,917	$	155,437

The components of lease cost were as follows:

Schedule of Lease Cost


	For six months ended September 30,
	2024		2023
Depreciation	$	37,184	$	60,680
Interest on lease obligation		4,807		20,861
Total lease cost	$	41,991	$	81,541

Lease term and discount rate were as follows:

Schedule Lease Term and Discount Rate

	For the six months ended September 30,
	2024			2023
Weighted average remaining lease term - Operating leases		2 years			2.75 years

Weighted average discount rate - Operating leases		3	%		3	%

F-13

Note 7 - Intangible Assets

Intangible assets, consisted of the following:

Schedule of Intangible Assets


	As of
	September 30, 2024			March 31, 2024
Telemedicine Property	$	17,806		$	17,806
Web Properties		—			—
Domain		24,323			19,323
Software		—			—
Intangible assets, gross		—			—
Accumulated Amortization		(12,354	)		(8,688	)
Net Balance	$	29,775		$	28,441

Amortization expense for the six months ended September 30, 2024 was $3,666 and $921 for the six months ended September 30, 2023.

Note 8 - Goodwill

Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in the business combinations. On November 08, 2022, the Company acquired 100% of the outstanding equity shares of RxCompoundStore.com, LLC and Peaks Curative, LLC against the share exchange consideration and recognized Goodwill. Restated Financial Statements were issued for year ended March 31, 2023, 10- K Form, to correct Goodwill amortization during the period.

Schedule of Goodwill

	As of
	September 30, 2024		March 31, 2024
RxCompound and Peaks	$	2,302,792	$	2,302,792

Total	$	2,302,792	$	2,302,792

The Company conducted an impairment test as of September 30, 2024, and March 31, 2024, and no indication of impairment was identified

F-14

Note 9 - Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:


	As of
	September 30, 2024		March 31, 2024
Accounts Payable	$	392,227	$	530,724
Accrued Expenses and other payable (A)	$	1,158,238	$	854,719

(A)

Accrued Expenses and other payable

As of September 30, 2024, accrued expenses included approximately; officer compensation of $838,000, insurance payable $72,000, payroll liability $81,000, merchant fees of $93,000, and credit card balance of $66,000, as March 31, 2024, accrued expenses included executive compensation of approximately $650,000, and $68,000 in merchant fees.

Note 10 – Debt

Loans and Notes Payable consisted of the following

Schedule of Notes and Loans Payable

Name	Total		Current		Non-Current
As of September 30, 2024
Equipment Finance	$	79,114	$	30,592	$	48,522
As of March 31, 2024
Equipment Finance	$	91,151	$	30,592	$	60,559

No additional debt was incurred during the period.

Note 11 - Related Party Balances and Transactions

Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial and operating decisions. Transactions with related parties have been disclosed officer’s compensation notes. Additionally, for the six months ended September 30, 2024 the Company reimbursed Point 96 Consulting LLC for consulting services, marketing, and SG&A in the amount of $439,000.

Officer compensation for the three months ended September 30, 2024 was $2,679,308 and, $5,385,912 for the six months ended September 30, 2024, paid to Point 96 Consulting owned by Giorgio R. Saumat and Tabraue Consulting, owned by Mario Tabraue.

During the three months ended September 30, 2024, the Company paid Avenvi LLC $115,303 for stock repurchases, and for the six months ended September 30, 2024, the Company paid Avenvi LLC $273,776 for stock repurchases.

F-15

Note 12 – Commitment and Contingencies

On August 15, 2024, the Board of Directors of Earth Science Tech, Inc., a Florida corporation (the “Company”), approved a new twelve-month Employment Agreement for its officers Giorgio R. Saumat, the Company’s CEO and Chairman of the Board, and Mario G. Tabraue, the Company’s COO and Director of the Board, entered on August 16, 2024. Under the new agreement, the CEO shall receive eighteen percent of the Company’s monthly cash receipts while the COO shall receive twelve percent. Payments will commence on October 1, 2024, and will be based on the preceding month’s cash receipts, provided the Company’s net profit increases quarter over quarter. If the Company fails to increase its net profit, the arrangement must be renegotiated, with no payments made at the beginning of the new quarter. Additionally, the COO has agreed to relinquish all current roles held in the Company’s wholly owned subsidiaries, along with the associated compensation, in order to focus exclusively on his duties as COO. This adjustment reflects the COO’s commitment to the new role and revised scope of responsibilities.

The Company follows ASC 450 to account for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. This may result in contingent liabilities that are required to be accrued or disclosed in the financial statements. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s consolidated financial position, results of operations, or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.

Legal Matters:

From time to time and in the course of business, we may become involved in various legal proceedings seeking monetary damages and other relief. The amount of the ultimate liability, if any, from such claims cannot be determined. As of the date hereof, there are no legal claims currently pending or, to our knowledge, threatened against us or any of our officers or directors in their capacity as such or against any of our properties that, in the opinion of our management, would be likely to have a material adverse effect on our financial position, results of operations or cash flows.

Note 13 – Stockholders’ Equity

During the six months ended September 30, 2024, and 2023, the Company did not issue any shares of restricted common stock.

During the six months ended September 30, 2024, and 2023, the Company did not issue any shares of common stock at fair value.

During the six months ended September 30, 2024, and 2023, the Company repurchased 6,345,896 shares and 0 shares of common stock at fair value of $922,795 and $0 respectively.

As of September 30, 2024, the Company has repurchased a total of 11,545,898 shares of its common stock out of its five million dollar common stock repurchase program initiated on January 29, 2024. Repurchases have been made at management’s discretion from time to time through privately negotiated transactions. The repurchase program expires December 31, 2025, but may be suspended for periods or discontinued at any time, and does not obligate the Company to acquire any particular number of shares.

Note 14 – Subsequent Events

On October 1, 2024, Earth Science Tech, Inc., a Florida corporation (the “Company”), completed the acquisition of Avenvi, LLC., (“Avenvi”), a Florida limited liability company owned by Giorgio R. Saumat, as an asset acquisition for a total of $1,058,788., with an initial payment of $258,788, followed by subsequent monthly payments of $200,000 for the next four months. The acquisition encompasses approximately four acres of vacant residential real estate intended for development, one commercial property comprising nearly half an acre featuring a standalone building with five thousand square feet, and cash or cash equivalents held by Avenvi. Visit: avenvi.com.

Related Party Transaction

Giorgio R. Saumat, who currently serves as the Company’s Chief Executive Officer (CEO) and the Chairman of Board, is the seller in this transaction. The transaction was reviewed and approved by the Board of Directors to ensure that the terms were no less favorable to the Company than those that could be obtained from unaffiliated third parties.

On October 3, 2024, the Company completed the acquisition of Mister Meds, LLC, a Texas limited liability company, Owned by Mario G. Tabraue for fifty-four thousand two hundred dollars cash, as an asset acquisition.

Related Party Transaction

Mario G. Tabraue, who currently serves as the Company’s Chief Operations Officer (COO) and is a Director of the Board, is the seller in this transaction. The transaction was reviewed and approved by the Board of Directors to ensure that the terms were no less favorable to the Company than those that could be obtained from unaffiliated third parties.

On October 1, 2024, the company expanded into the pet and wildlife industry by launching Zoolzy, a brand under Peaks Curative, LLC. Zoolzy specializes in providing compounded medications tailored by RxCompoundstore.com, LLC., to the unique health needs of pets and wildlife. Visit: Zoolzy.com

On October 1, 2024, the Company relocated its principal office to 8950 SW 74^th CT Suite 1401, Miami, FL 33156. The new office spans approximately one thousand one hundred twenty-five square feet, adding to the existing two thousand five hundred square feet of administrative space. This brings the Company’s total space to around seven thousand one hundred twenty-five total square feet, which includes approximately three thousand one hundred twenty-five square feet of administrative space, about two thousand square feet dedicated to pharmacy operations, and around one thousand five hundred square feet for off-site storage.

F-16

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

The following section, Management’s Discussion and Analysis, should be read in conjunction with Earth Science Tech, Inc.’s financial statements and the related notes thereto and contains forward-looking statements that involve risks and uncertainties, such as statements of the Company’s plans, objectives, expectations, and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect,” and the like, and/or future-tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements in this Report on Form 10-Q. The Company’s actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of many factors. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Report filed on Form 10-Q.

The following discussion should be read in conjunction with the company’s unaudited consolidated financial statements and related notes and other financial data included elsewhere in this report. See also the notes to the Company’s consolidated financial statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in the Company’s Registration Statement filed on Form 10-12g and the Company’s Annual Report filed on Form 10-K for the fiscal year ended March 31, 2024, as well as the Company’s Quarterly report filed on Form 10-Q for the fiscal quarter ended June 30, 2024.

OVERVIEW

The Company is a holding entity set to acquire companies with its current focus in the health and wellness industry. The Company is presently in compounding pharmaceuticals and telemedicine through its wholly owned subsidiaries RxCompound, Peaks, and ESF.

Peaks is the telemedicine referral site facilitating asynchronous consultations for branded compound medications prepared at RxCompound. Peaks is currently positioned to prescribe to all 50 states utilizing third-party consultation services, but only able to fulfill prescriptions within RxCompound’s licensed states. Peaks will be able to fulfill more states as RxCompound becomes licensed in additional states.

Results of Operations

The following tables set forth summarized cost of revenue information for the three months ended September 30, 2024, and 2023:

	For the Three Months Ended September 30,				For the Six Months Ended September 30,
	2024		2023		2024		2023
Revenue	$	8,519,047	$	1,927,720	$	17,087,965	$	2,147,654
Cost of Goods Sold		2,252,366		746,226		4,410,850		817,391
Gross Profit	$	6,266,681	$	1,181,494	$	12,677,115	$	1,330,263

We had product sales of $8,519,047 and a gross profit of $6,266,681 representing a gross margin of 73% in the fiscal quarter ended September 30, 2024, compared with product sales of $1,927,720 and a gross profit of $1,181,494 representing a gross margin of 61% in the fiscal quarter ended September 30, 2023. The revenue increase during the three months ended September 30, 2024, compared with the three months ended September 30, 2023, is primarily due to an increase of sales through new accounts.

Operating Expenses

	For the three months ended September 30,												For the six months ended September 30,
	2024			2023			change			% change			2024			2023			change			% change
Salaries Expense		3,605,954			193,917			3,412,037			95	%		6,941,084			258,305			6,682,779			96	%
General and Administrative Expenses		1,259,422			93,962			1,165,460			93	%		2,580,405			161,462			2,418,943			94	%
Bank Charges		271,452						271,452			100	%		560,297			-			560,297			100	%
Marketing		152,520			5,148			147,372			97	%		363,966			16,524			347,442			95	%
Legal and Professional fees		63,259			407,626			(344,367	)		-544	%		181,706			424,546			(242,840	)		-134	%
Insurance Expense		45,021						45,021			100	%		80,826			-			80,826			100	%
Depreciation and Amortization		33,191			1,097			32,094			97	%		63,423			64,093			(670	)		-1	%
Utilities		6,302						6,302			100	%		10,830			-			10,830			100	%
Total Expenses		5,437,121			701,750			4,735,371			87	%		10,782,537			924,930			9,857,607			91	%
Net Operating Income		829,560			479,944			349,616			42	%		1,894,578			405,333			1,489,245			79	%
Other Income/Expenses
Other Income					(452	)		452			-100	%		13,200			(452	)		13,652			103	%
Interest Expense		(2,843	)		(34,911	)		32,068			-1128	%		(4,807	)		(47,509	)		42,702			-888	%
Net Income before taxes		826,717			444,581			382,136			46	%		1,902,971			357,372			1,545,599			81	%
Income Taxes		28,349									100	%		28,349			-			28,349			100	%
Net Income	$	798,368		$	444,581			353,787			44	%	$	1,874,622		$	357,372			1,517,250			81	%

For the three months ended September 30, 2024, Salaries expense increased to $3,605,954, this is attributable to the rapid growth the Company has experienced, hence the necessity to hire new employees, and the executive team’s new compensation agreement has been put in place.

General and administrative expenses increase from $93,962 for the three months ended September 30, 2023, to $1,259,422, this is due to the area managers fees to support clients out of state , for the six months ended September 30, 2024 increased from $161,462 to $2,580,405.

Bank charges for the three months ended September 30, 2024, totalled $271,452, this is directly related to credit card processing fees.

Marketing expenses totaled $152,520 for the three months ended September 30, 2024, and $5,148 for three months ended on September 30, 2023, this increase had been contemplated by management as part of the strategic plan to increase sales, for the six months ended September 30, 2024 marketing expense was $363,966 versus $16,524 in 2023.

Legal and professional fees totaled $63,259 for the three months ended September 30, 2024, and $407,626 for the three months ended September 30, 2023.

We are a smaller reporting company, as defined by 17 CFR § 229.10(f)(1). We do not consider the impact of inflation and changing prices as having a material effect on our net sales and revenues and on income from our operations for the previous two years or from continuing operations going forward.

Interest Expense

Interest expense for the three months ended September 30, 2024, was $2,843 vs $34,911 in the three months ended September 30, 2023. This 92% reduction of interest expense is attributable to the Company paying off a large portion of its long-term debt.

We use Adjusted EBITDA internally to evaluate our performance and make financial and operational decisions that are presented in a manner that adjusts from their equivalent GAAP measures or that supplements the information provided by our GAAP measures. Adjusted EBITDA is defined by us as EBITDA (net income (loss) plus depreciation expense, amortization expense, interest and income tax expense, minus income tax benefit), further adjusted to exclude certain non-cash expenses and other adjustments as set forth below. We use Adjusted EBITDA because we believe it more clearly highlights trends in our business that may not otherwise be apparent when relying solely on GAAP financial measures, since Adjusted EBITDA eliminates from our results specific financial items that have less bearing on our core operating performance.

We use Adjusted EBITDA in communicating certain aspects of our results and performance, including in this Quarterly Report, and believe that Adjusted EBITDA, when viewed in conjunction with our GAAP results and the accompanying reconciliation, can provide investors with greater transparency and a greater understanding of factors affecting our financial condition and results of operations than GAAP measures alone. In addition, we believe the presentation of Adjusted EBITDA is useful to investors in making period-to-period comparison of results because the adjustments to GAAP are not reflective of our core business performance.

Adjusted EBITDA is not presented in accordance with, or as an alternative to, GAAP financial measures and may be different from non-GAAP measures used by other companies. We encourage investors to review the GAAP financial measures included in this Annual Report, including our consolidated financial statements, to aid in their analysis and understanding of our performance and in making comparisons.

Assets and Cash Flows

	As of September 30, 2024		As of March 31, 2024
	(Unaudited)		Audited
ASSETS
Current Assets		2,281,088		1,258,234
Total Assets	$	5,049,628	$	3,881,336
Total Liabilities		1,848,496		1,632,031

	For the six months ended September 30,
	2024			2023
Net cash provided by operating activities	$	1,877,917		$	127,910
Net cash used in investing activities		(108,595	)		—
Net cash used/provided by financing activities		(934,832	)		23,984
Net increase in cash and cash equivalents		834,490			151,894
Cash and cash equivalents at beginning of the period		697,721			35,756
Cash and cash equivalents at end of the period	$	1,532,211		$	187,650

The Company had $1,532,211 cash as of September 30, 2024, compared to $187,650 as of September 30, 2023.

Accounts receivable as of September 30, 2024, were $203,942, and 100% is expected to be collected within term.

The Company has made a $22,608 lease security deposit, which is fully refundable at the end of the lease period.

The Company has prepaid its liability insurance for the year totaling $90,110.

The Company’s subsidiaries, RxCompound and Peaks Curative have made additional capital expenditures as of September 30, 2024, and have a total net balance of $216,346 in property and equipment, versus $135,352 as of March 31, 2024.

As of September 30, 2024, the Company had $482,217 in inventory vs $315,738 as of March 31, 2024.

The Company had a balance of $392,227 in Accounts Payable as of September 30, 2024, compared to $530,724 as of March 31, 2024.

Accrued expenses totaled $1,158,238 as of September 30, 2024, and $854,719 as of March 31, 2024. Most accrued expenses as of September 30, 2024, are attributable to officer compensation.

The Stockholders’ Equity as of September 30, 2024, was $3,201,132, compared to $2,249,305 of Stockholders Equity as of March 31, 2024. This improvement is primarily attributable to the results of operations.

Cash Flow from Operating Activities

Net cash provided by operating activities for the six months ended September 30, 2024, was $1,877,917, compared to $127,909 provided by operating activities for the prior year period. The increase in cash flows from the prior year period is primarily driven by the results of operations.

Net cash from investing activities during the six months ended September 30, 2024, was $108,595.

Cash Flows from Financing Activities

Net cash used in financing activities during the six months ended September 30, 2024, was 934,832, of which $922,795 was repurchased of shares.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired control objectives. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

The Company’s management, including the Chief Executive Officer and Chief Financial Officer have reviewed and evaluated the effectiveness of the Company’s design and operations of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that review and evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this Quarterly Report, the Company’s disclosure controls and procedures were effective as of September 30, 2024.

Management’s Report on Internal Control Over Financial Reporting

Our disclosure controls and procedures contain components of our internal controls over financial reporting. Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the Company’s principal executive and financial officer and effected by the Company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company.

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

The Company’s management assessed the effectiveness of the Company’s internal control over financial reporting as of the Evaluation Date. In making this assessment, the Company’s management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) Internal Control-Integrated Framework (2013). The COSO framework is based upon five integrated components of control: control environment, risk assessment, control activities, information and communications and ongoing monitoring.

Based on an evaluation under the supervision of and with the participation of, the Company’s management, including the Chief Executive Officer and Chief Financial Officer, Company management has concluded that the Company’s internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act was reasonably effective as of the Evaluation Date, and will continue to improve, to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control and Financial Reporting

During the quarter ended September 30, 2024, the company has continued to make process improvement changes in the internal control over financial reporting which are reasonably likely to significantly improve the internal control over financial reporting. The impact of these changes made is still under evaluation as of the quarter ended September 30, 2024.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

ITEM 1A. RISK FACTORS

The Company is a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and is not required to provide the information under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended September 30, 2024, the Company issued 0 shares of its common stock for $0, in transactions that were exempt from registration under the Securities Act of 1933, as amended pursuant to Section 4(2) and/or Rule 506 promulgate under Regulation D. No gain or loss was recognized on the issuances.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

None

ITEM 5. OTHER INFORMATION

ISSUER REPURCHASES OF EQUITY SECURITIES

During the six months ended September 30, 2024, the Company repurchased 6,345,896 shares of its common stock for $922,795 in private transactions through Stock Purchase Agreements with certain shareholders. On June 4, 2024, the Company repurchased 914,108 shares from an investor at $0.1734 per share in cash. On July 1, 2024, the Company repurchased 725,727 shares from an investor at $0.2346 per share. On July 9,2024, the Company repurchased 17,000 shares from an investor at $0.28 per share. On July 11 ,2024, the Company repurchased 70,000 shares from an investor at $0.13 per share. On July 26, 2024, the Company repurchased 1,500,000 shares from an investor at $0.13 per share. On August 6, 2024, the Company repurchased 2,500,000 shares from an investor at $0.105 per share. On August 6, 2024, the Company repurchased 70,000 shares from an investor at $0.105 per share. On August 27, 2024, the Company repurchased 549,061 shares from an investor at $0.21 per share.

During the three months ended September 30, 2024, the Company repurchased 5,431,788 shares of its common stock for $764,315.60, in private transactions through Stock Purchase Agreements with certain shareholders. On July 1, 2024, the Company repurchased 725,727 shares from an investor at $0.2346 per share. On July 9, 2024, the Company repurchased 17,000 shares from an investor at $0.28 per share. On July 11, 2024, the Company repurchased 70,000 shares from an investor at $0.13 per share. On July 26, 2024, the Company repurchased 1,500,000 shares from an investor at $0.13 per share. On August 6, 2024, the Company repurchased 2,500,000 shares from an investor at $0.105 per share. On August 6, 2024, the Company repurchased 70,000 shares from an investor at $0.105 per share. On August 27, 2024, the Company repurchased 549,061 shares from an investor at $0.21 per share.

ITEM 6. EXHIBITS

31.1		Certifications of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *

31.2		Certifications of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *

32.1		Certifications of Chief Executive Officer pursuant to 18 U.S.C. SEC. 1350 (Section 906 of Sarbanes-Oxley Act of 2002) +

32.2		Certifications of Chief Financial Officer pursuant to 18 U.S.C. SEC. 1350 (Section 906 of Sarbanes-Oxley Act of 2002) +

101.INS		Inline XBRL Instance Document *

101.SCH		Inline XBRL Taxonomy Extension Schema Document *

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document *

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document *

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document *

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document *

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EARTH SCIENCE TECH, INC.

Dated: November 14, 2024	By:	/s/ Giorgio R. Saumat
		Giorgio R. Saumat
	Its:	CEO and Chairman of the Board

Dated: November 14, 2024	By:	/s/ Ernesto Flores
		Ernesto Flores,
	Its:	Chief Financial Officer

Exhibit 31.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14

I, Giorgio R. Saumat, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Earth Science Tech, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under the Company’s supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report the Company’s conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on the Company’s most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	EARTH SCIENCE TECH, INC.

Dated: November 14, 2024	By:	/s/ Giorgio R. Saumat
		Giorgio R. Saumat
	Its:	CEO and Chairman of the Board

Exhibit 31.2

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14

I, Ernesto Flores, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Earth Science Tech, Inc.;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report the company’s conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	EARTH SCIENCE TECH, INC.

Dated: November 14, 2024	By:	/s/ Ernesto Flores
		Ernesto Flores,
	Its:	Chief Financial Officer

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Earth Science Tech, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ending September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Giorgio R. Saumat, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	EARTH SCIENCE TECH, INC.

Dated: November 14, 2024	By:	/s/ Giorgio R. Saumat
		Giorgio R. Saumat
	Its:	CEO and Chairman of the Board

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Earth Science Tech, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ending September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ernesto Flores, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	EARTH SCIENCE TECH, INC.

Dated: November 14, 2024	By:	Ernesto Flores
		Ernesto Flores
	Its:	Chief Financial Officer

Cover	6 Months Ended
Cover	Sep. 30, 2024 shares
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--03-31
Entity File Number	000-55000
Entity Registrant Name	EARTH SCIENCE TECH, INC.
Entity Central Index Key	0001538495
Entity Tax Identification Number	80-0931484
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	8950 SW 74th CT
Entity Address, Address Line Two	Suite 1401
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33156
City Area Code	(305)
Local Phone Number	724-5684
Title of 12(b) Security	Common Stock $0.001 par value
Trading Symbol	ETST
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	303,635,893

Consolidated Balance Sheets (Unaudited) - USD ($)

Sep. 30, 2024

Mar. 31, 2024

Current Assets:

Cash

$ 1,532,211

$ 697,721

Accounts Receivable

203,942

235,423

Deposits

22,608

9,352

Inventory

432,217

315,738

Prepaid

90,110

Total current assets

2,281,088

1,258,234

Non-Current Assets:

Property and Equipment, net

216,346

135,352

Right of use asset, net

219,627

156,517

Goodwill

2,302,792

Intangible Assets, net

29,775

28,441

Total Assets

5,049,628

3,881,336

LIABILITIES AND EQUITY

Accounts payable

392,227

530,724

Accrued expenses and other payable

^[1]

1,158,238

854,719

Current portion of operating lease obligations

118,227

70,487

Current portion of loans and obligations

30,592

Total Current Liabilities

1,699,284

1,486,522

Long-Term Liabilities:

Lease liability less current maturities

100,690

84,950

Equipment loans and obligations non-current

48,522

60,559

Total Liabilities

1,848,496

1,632,031

Commitment and Contingencies ( Note 12)

Stockholders’ Equity:

Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 0 shares issued and outstanding as of September 30, 2024, and March 31, 2024, respectively

1,000

Common stock, par value $0.001 per share, 350,000,000 shares authorized; 303,635,923 and 309,981,819 shares issued and outstanding as of September 30, 2024, and March 31, 2024 respectively

303,636

309,982

Additional paid-in capital

30,676,950

31,593,399

Accumulated deficit

(27,780,454)

(29,655,076)

Total stockholders’ Equity

3,201,132

2,249,305

Total Liabilities and Equity

$ 5,049,628

$ 3,881,336

[1]	Accrued Expenses and other payable

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2024	Mar. 31, 2024
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	0
Preferred stock, shares outstanding	1,000,000	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	303,635,923	309,981,819
Common stock, shares outstanding	303,635,923	309,981,819

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenue	$ 8,519,047	$ 1,927,720	$ 17,087,965	$ 2,147,654
Cost of Goods Sold (exclusive of depreciation shown separately below)	2,252,366	746,226	4,410,850	817,391
Gross Profit	6,266,681	1,181,494	12,677,115	1,330,263
Expenses:
Salaries Expense	3,605,954	193,917	6,941,084	258,305
General and Administrative Expense	1,259,422	93,962	2,580,405	161,462
Bank Charges	271,452		560,297
Marketing	152,520	5,148	363,966	16,524
Legal and Professional Fees	63,259	407,626	181,706	424,546
Insurance Expense	45,021		80,826
Depreciation and Amortization	33,191	1,097	63,423	64,093
Utilities	6,302		10,830
Total Expenses	5,437,121	701,750	10,782,537	924,930
Net Operating Income	829,560	479,944	1,894,578	405,333
Other Income/Expenses
Other Income		(452)	13,200	(452)
Interest expense	(2,843)	(34,911)	(4,807)	(47,509)
Net Income before taxes	826,717	444,581	1,902,971	357,372
Income Taxes	28,349		28,349
Net Income	$ 798,368	$ 444,581	$ 1,874,622	$ 357,372
Profit/(Loss) per common share - Basic	$ 0.003	$ 0.001	$ 0.006
Profit/(Loss) per common share - Diluted	$ 0.003	$ 0.001	$ 0.006	$ 0.001
Weighted average number of common shares outstanding basic	306,047,031	314,881,821	307,989,312	314,881,821
Weighted average number of common shares outstanding diluted	306,047,031	314,881,821	307,989,312	314,881,821

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Mar. 31, 2023	$ 282,612	$ 1,000	$ 31,303,138	$ (30,467,214)	$ 1,119,535
Balance, shares at Mar. 31, 2023	282,611,083	1,000,000
Common stock buyback					$ 0
Common stock buyback, shares					0
Net Income (Loss)				357,372	$ 357,372
Common stock issued for cash	$ 18,534		91,467		110,001
Common stock issued for cash, shares	18,533,334
Common stock issued for conversion of note payable	$ 13,406		371,594		385,000
Common stock issued for Conversion on Note, shares	13,406,313
Balance at Sep. 30, 2023	$ 314,552	$ 1,000	31,766,199	(30,109,842)	1,971,909
Balance, shares at Sep. 30, 2023	314,550,730	1,000,000
Balance at Jun. 30, 2023	$ 314,552	$ 1,000	31,766,199	(30,554,423)	1,527,328
Balance, shares at Jun. 30, 2023	314,550,730	1,000,000
Net Income (Loss)				444,581	444,581
Balance at Sep. 30, 2023	$ 314,552	$ 1,000	31,766,199	(30,109,842)	1,971,909
Balance, shares at Sep. 30, 2023	314,550,730	1,000,000
Balance at Mar. 31, 2024	$ 309,982	$ 1,000	31,593,399	(29,655,076)	2,249,305
Balance, shares at Mar. 31, 2024	309,981,819	1,000,000
Common stock buyback	$ (6,346)		(916,449)		$ (922,795)
Common stock buyback, shares	(6,345,896)				6,345,896
Net Income (Loss)				1,874,622	$ 1,874,622
Balance at Sep. 30, 2024	$ 303,636	$ 1,000	30,676,950	(27,780,454)	3,201,132
Balance, shares at Sep. 30, 2024	303,635,923	1,000,000
Balance at Jun. 30, 2024	$ 309,068	$ 1,000	31,435,840	(28,578,822)	3,167,086
Balance, shares at Jun. 30, 2024	309,067,711	1,000,000
Common stock buyback	$ (5,432)		(758,890)		(764,322)
Common stock buyback, shares	(5,431,788)
Net Income (Loss)				798,368	798,368
Balance at Sep. 30, 2024	$ 303,636	$ 1,000	$ 30,676,950	$ (27,780,454)	$ 3,201,132
Balance, shares at Sep. 30, 2024	303,635,923	1,000,000

Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net Income	$ 1,874,622	$ 357,372
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	63,423	64,093
Changes in operating assets and liabilities:
Accounts Receivable	31,481	(62,860)
Deposits	(13,256)
Prepaid expenses and other current assets	(90,110)
Inventory	(116,478)	(200,980)
Other current liabilities		28,000
Lease Liability, net	(36,814)	(34,094)
Accrued settlement		(185,947)
Accounts payable and accrued expenses	165,049	162,326
Net cash provided in operating activities	1,877,917	127,910
Cash flows from investing activities:
Purchases of property and equipment and intangibles	(108,595)
Net cash used in investing activities	(108,595)
Cash flows from financing activities:
Proceeds from issuance of common stock		110,001
Payments on debt obligations	(12,037)	(86,017)
Repurchase of common stock	(922,795)
Net Cash provided by (used) in financing activities	(934,832)	23,984
Net increase in cash and cash equivalents	834,490	151,894
Cash and cash equivalents at beginning of the period	697,721	35,756
Cash and cash equivalents at end of the period	1,532,211	187,650
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	4,807
Cash paid for income taxes	28,349
Non-Cash Transactions
Initial recognition of right of use asset	100,294
Common stock issued on conversion of notes payable		$ 385,000

Organization and Nature of Operations

6 Months Ended

Sep. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Nature of Operations

Note 1 — Organization and Nature of Operations

These financial statements should be read in conjunction with audited consolidated financial statements and notes.

Summary of Significant Accounting Policies

6 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 — Summary of Significant Accounting Policies

Basis of presentation

Principles of consolidation

Use of estimates and assumptions

Carrying value, recoverability, and impairment of long-lived assets

Cash and cash equivalents

Accounts Receivable.

Schedule of Accounts Receivable


	As of
	September 30, 2024		March 31, 2024
Accounts Receivable	$	203,942	$	235,423

Revenue recognition

Disaggregated Revenue

The Company’s disaggregated revenue by category is as follows:

Schedule of Disaggregated Revenue


	For the six months ended September 30,
	2024		2023
Core:
Sale of Pharmaceutical products – RxCompound and Peaks	$	16,563,906	$	2,147,654
Total core revenue, net	$	16,563,906	$	2,147,654
Non-Core:
Shipping Income	$	524,059	$	—
Total revenue, net	$	17,087,965	$	2,147,654

The Company currently has three large customers, each representing 14%, 12% and 9% of revenue for the six months ended September 30, 2024.

Inventory

Cost of Goods Sold

Components of cost of goods sold include product costs, consumables, shipping costs to customers and any inventory adjustments.

Shipping and Handling Costs

Costs incurred by the Company for shipping and handling are included in costs of revenues.

Related parties

The Company pays the employee compensation for Giorgio R. Saumat and Mario Tabraue to their respective, solely owned LLCs, Point96 Consulting, LLC and Tabraue Consulting, LLC.

Income taxes

Net income per common share

Cash flows reporting

Goodwill

Stock based compensation

Fair Value

Level 1 — Quoted market prices for identical assets or liabilities in active markets or observable inputs; and

Level 2 — Significant other observable inputs that can be corroborated by observable market data; and

Level 3 — Significant unobservable inputs that cannot be corroborated by observable market data.

The carrying amounts of cash, accounts payable and other liabilities, accrued expenses and settlement payable approximate fair value because of the short-term nature of these items.

Property and equipment

Recently issued accounting pronouncements

We have considered the impact of the following pronouncements:

Intangible Assets

Intangible assets consist of Peaks telemedicine platform, and the Holding Company’s web domains. Intangible assets with finite lives are amortized over the estimated useful life of five years.

Restatement

6 Months Ended

Sep. 30, 2024

Accounting Changes and Error Corrections [Abstract]

Restatement

Note 3 – Restatement

Schedule of Effect of Restatement

Adjustments to Consolidated Balance Sheet as of September 30, 2023

Consolidated Balance Sheet


	As of September 30, 2023
	September 30, 2023, before restatement		Restatement		September 30,2023 after restatement
Total Assets	$	3,041,344	$	38,269	$	3,079,613
Total stockholders’ Equity		1,933,640		38,269		1,971,909

Adjustments to Consolidated Statement of Stockholders’ Equity for the six months ended September 30, 2023

Consolidated Statement of Stockholders’ Equity


	For the six months ended September 30, 2023
	September 30, 2023, before restatement			Restatement		September 30, 2023, after restatement
Accumulated deficit	$	(30,148,111	)	$	38,269	$	(30,109,842	)
Stockholders’ Equity		1,933,640			38,269		1,971,909

Adjustments to Consolidated Statement of Operations for the six months ended September 30, 2023

Consolidated Statement of Operations


	For the six months ended September 30, 2023
	September 30, 2023, before restatement		Restatement			September 30, 2023, after restatement
Net Income	$	354,872	$	(2,500	)	$	357,372

Inventory

6 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

Inventory

Note 4 - Inventory

Schedule of Inventory


	As of
	September 30, 2024		March 31, 2024
Raw materials	$	334,312		266,776
Finished goods		97,905		48,962
Inventory	$	432,217	$	315,738

Property and Equipment

6 Months Ended

Sep. 30, 2024

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 5 — Property and Equipment

Schedule of Property and Equipment


	As of
	September 30, 2024			March 31, 2024
Equipment – cost	$	280,197		$	176,602
Less: Accumulated depreciation		(63,851	)		(41,250	)
Property and Equipment, Net	$	216,346		$	135,352

Depreciation expense for the six months ended September 30, 2024, and September 30, 2023, was $22,601 and $14,370, respectively.

Leases

6 Months Ended

Sep. 30, 2024

Leases [Abstract]

Leases

Note 6 — Leases

Supplemental balance sheet information related to leases were as follows:


	As of
	September 30, 2024		March 31, 2024
Assets
Right of use asset, net	$	219,627	$	156,517

Operating lease liabilities
Current		118,227		70,487
Non-current		100,690		84,950
Total Lease Liabilities	$	218,917	$	155,437

The components of lease cost were as follows:

Schedule of Lease Cost


	For six months ended September 30,
	2024		2023
Depreciation	$	37,184	$	60,680
Interest on lease obligation		4,807		20,861
Total lease cost	$	41,991	$	81,541

Lease term and discount rate were as follows:

Schedule Lease Term and Discount Rate

	For the six months ended September 30,
	2024			2023
Weighted average remaining lease term - Operating leases		2 years			2.75 years

Weighted average discount rate - Operating leases		3	%		3	%

Intangible Assets

6 Months Ended

Sep. 30, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 7 - Intangible Assets

Intangible assets, consisted of the following:

Schedule of Intangible Assets


	As of
	September 30, 2024			March 31, 2024
Telemedicine Property	$	17,806		$	17,806
Web Properties		—			—
Domain		24,323			19,323
Software		—			—
Intangible assets, gross		—			—
Accumulated Amortization		(12,354	)		(8,688	)
Net Balance	$	29,775		$	28,441

Amortization expense for the six months ended September 30, 2024 was $3,666 and $921 for the six months ended September 30, 2023.

Goodwill

6 Months Ended

Sep. 30, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

Note 8 - Goodwill

Schedule of Goodwill

	As of
	September 30, 2024		March 31, 2024
RxCompound and Peaks	$	2,302,792	$	2,302,792

Total	$	2,302,792	$	2,302,792

The Company conducted an impairment test as of September 30, 2024, and March 31, 2024, and no indication of impairment was identified

Accounts Payable and Accrued Expenses

6 Months Ended

Sep. 30, 2024

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

Note 9 - Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:


	As of
	September 30, 2024		March 31, 2024
Accounts Payable	$	392,227	$	530,724
Accrued Expenses and other payable (A)	$	1,158,238	$	854,719

(A)

Accrued Expenses and other payable

Debt

6 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

Debt

Note 10 – Debt

Loans and Notes Payable consisted of the following

Schedule of Notes and Loans Payable

Name	Total		Current		Non-Current
As of September 30, 2024
Equipment Finance	$	79,114	$	30,592	$	48,522
As of March 31, 2024
Equipment Finance	$	91,151	$	30,592	$	60,559

No additional debt was incurred during the period.

Related Party Balances and Transactions

6 Months Ended

Sep. 30, 2024

Related Party Balances and Transactions

Note 11 - Related Party Balances and Transactions

Commitment and Contingencies

6 Months Ended

Sep. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitment and Contingencies

Note 12 – Commitment and Contingencies

Legal Matters:

Stockholders’ Equity

6 Months Ended

Sep. 30, 2024

Equity [Abstract]

Stockholders’ Equity

Note 13 – Stockholders’ Equity

During the six months ended September 30, 2024, and 2023, the Company did not issue any shares of restricted common stock.

During the six months ended September 30, 2024, and 2023, the Company did not issue any shares of common stock at fair value.

During the six months ended September 30, 2024, and 2023, the Company repurchased 6,345,896 shares and 0 shares of common stock at fair value of $922,795 and $0 respectively.

Subsequent Events

6 Months Ended

Sep. 30, 2024

Subsequent Events [Abstract]

Subsequent Events

Note 14 – Subsequent Events

Related Party Transaction

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Basis of presentation

Basis of presentation

Principles of consolidation

Principles of consolidation

Use of estimates and assumptions

Use of estimates and assumptions

Carrying value, recoverability, and impairment of long-lived assets

Carrying value, recoverability, and impairment of long-lived assets

Cash and cash equivalents

Cash and cash equivalents

Accounts Receivable.

Accounts Receivable.

Schedule of Accounts Receivable


	As of
	September 30, 2024		March 31, 2024
Accounts Receivable	$	203,942	$	235,423

Revenue recognition

Revenue recognition

Disaggregated Revenue

Disaggregated Revenue

The Company’s disaggregated revenue by category is as follows:

Schedule of Disaggregated Revenue


	For the six months ended September 30,
	2024		2023
Core:
Sale of Pharmaceutical products – RxCompound and Peaks	$	16,563,906	$	2,147,654
Total core revenue, net	$	16,563,906	$	2,147,654
Non-Core:
Shipping Income	$	524,059	$	—
Total revenue, net	$	17,087,965	$	2,147,654

The Company currently has three large customers, each representing 14%, 12% and 9% of revenue for the six months ended September 30, 2024.

Inventory

Inventory

Cost of Goods Sold

Cost of Goods Sold

Components of cost of goods sold include product costs, consumables, shipping costs to customers and any inventory adjustments.

Shipping and Handling Costs

Shipping and Handling Costs

Costs incurred by the Company for shipping and handling are included in costs of revenues.

Related parties

Related parties

The Company pays the employee compensation for Giorgio R. Saumat and Mario Tabraue to their respective, solely owned LLCs, Point96 Consulting, LLC and Tabraue Consulting, LLC.

Income taxes

Income taxes

Net income per common share

Net income per common share

Cash flows reporting

Cash flows reporting

Goodwill

Goodwill

Stock based compensation

Stock based compensation

Fair Value

Fair Value

Level 1 — Quoted market prices for identical assets or liabilities in active markets or observable inputs; and

Level 2 — Significant other observable inputs that can be corroborated by observable market data; and

Level 3 — Significant unobservable inputs that cannot be corroborated by observable market data.

The carrying amounts of cash, accounts payable and other liabilities, accrued expenses and settlement payable approximate fair value because of the short-term nature of these items.

Property and equipment

Property and equipment

Recently issued accounting pronouncements

Recently issued accounting pronouncements

We have considered the impact of the following pronouncements:

Intangible Assets

Intangible Assets

Intangible assets consist of Peaks telemedicine platform, and the Holding Company’s web domains. Intangible assets with finite lives are amortized over the estimated useful life of five years.

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Schedule of Accounts Receivable


	As of
	September 30, 2024		March 31, 2024
Accounts Receivable	$	203,942	$	235,423

Schedule of Disaggregated Revenue

The Company’s disaggregated revenue by category is as follows:

Schedule of Disaggregated Revenue


	For the six months ended September 30,
	2024		2023
Core:
Sale of Pharmaceutical products – RxCompound and Peaks	$	16,563,906	$	2,147,654
Total core revenue, net	$	16,563,906	$	2,147,654
Non-Core:
Shipping Income	$	524,059	$	—
Total revenue, net	$	17,087,965	$	2,147,654

Restatement (Tables)

6 Months Ended

Sep. 30, 2024

Accounting Changes and Error Corrections [Abstract]

Schedule of Effect of Restatement

Schedule of Effect of Restatement

Adjustments to Consolidated Balance Sheet as of September 30, 2023

Consolidated Balance Sheet


	As of September 30, 2023
	September 30, 2023, before restatement		Restatement		September 30,2023 after restatement
Total Assets	$	3,041,344	$	38,269	$	3,079,613
Total stockholders’ Equity		1,933,640		38,269		1,971,909

Adjustments to Consolidated Statement of Stockholders’ Equity for the six months ended September 30, 2023

Consolidated Statement of Stockholders’ Equity


	For the six months ended September 30, 2023
	September 30, 2023, before restatement			Restatement		September 30, 2023, after restatement
Accumulated deficit	$	(30,148,111	)	$	38,269	$	(30,109,842	)
Stockholders’ Equity		1,933,640			38,269		1,971,909

Adjustments to Consolidated Statement of Operations for the six months ended September 30, 2023

Consolidated Statement of Operations


	For the six months ended September 30, 2023
	September 30, 2023, before restatement		Restatement			September 30, 2023, after restatement
Net Income	$	354,872	$	(2,500	)	$	357,372

Inventory (Tables)

6 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

Schedule of Inventory


	As of
	September 30, 2024		March 31, 2024
Raw materials	$	334,312		266,776
Finished goods		97,905		48,962
Inventory	$	432,217	$	315,738

Property and Equipment (Tables)

6 Months Ended

Sep. 30, 2024

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment


	As of
	September 30, 2024			March 31, 2024
Equipment – cost	$	280,197		$	176,602
Less: Accumulated depreciation		(63,851	)		(41,250	)
Property and Equipment, Net	$	216,346		$	135,352

Leases (Tables)

6 Months Ended

Sep. 30, 2024

Leases [Abstract]

Schedule of Supplemental Balance Sheet Related To Leases

Supplemental balance sheet information related to leases were as follows:


	As of
	September 30, 2024		March 31, 2024
Assets
Right of use asset, net	$	219,627	$	156,517

Operating lease liabilities
Current		118,227		70,487
Non-current		100,690		84,950
Total Lease Liabilities	$	218,917	$	155,437

Schedule of Lease Cost

The components of lease cost were as follows:

Schedule of Lease Cost


	For six months ended September 30,
	2024		2023
Depreciation	$	37,184	$	60,680
Interest on lease obligation		4,807		20,861
Total lease cost	$	41,991	$	81,541

Schedule Lease Term and Discount Rate

Lease term and discount rate were as follows:

Schedule Lease Term and Discount Rate

	For the six months ended September 30,
	2024			2023
Weighted average remaining lease term - Operating leases		2 years			2.75 years

Weighted average discount rate - Operating leases		3	%		3	%

Intangible Assets (Tables)

6 Months Ended

Sep. 30, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets, consisted of the following:

Schedule of Intangible Assets


	As of
	September 30, 2024			March 31, 2024
Telemedicine Property	$	17,806		$	17,806
Web Properties		—			—
Domain		24,323			19,323
Software		—			—
Intangible assets, gross		—			—
Accumulated Amortization		(12,354	)		(8,688	)
Net Balance	$	29,775		$	28,441

Goodwill (Tables)

6 Months Ended

Sep. 30, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

	As of
	September 30, 2024		March 31, 2024
RxCompound and Peaks	$	2,302,792	$	2,302,792

Total	$	2,302,792	$	2,302,792

Accounts Payable and Accrued Expenses (Tables)

6 Months Ended

Sep. 30, 2024

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:


	As of
	September 30, 2024		March 31, 2024
Accounts Payable	$	392,227	$	530,724
Accrued Expenses and other payable (A)	$	1,158,238	$	854,719

Debt (Tables)

6 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

Schedule of Notes and Loans Payable

Loans and Notes Payable consisted of the following

Schedule of Notes and Loans Payable

Name	Total		Current		Non-Current
As of September 30, 2024
Equipment Finance	$	79,114	$	30,592	$	48,522
As of March 31, 2024
Equipment Finance	$	91,151	$	30,592	$	60,559

Schedule of Accounts Receivable (Details) - USD ($)	Sep. 30, 2024	Mar. 31, 2024
Accounting Policies [Abstract]
Accounts Receivable	$ 203,942	$ 235,423

Schedule of Disaggregated Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
Schedule of Disaggregated Revenue (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Product Information [Line Items]
Total revenue, net	$ 8,519,047	$ 1,927,720	$ 17,087,965	$ 2,147,654
Core [Member]
Product Information [Line Items]
Total revenue, net			16,563,906	2,147,654
Noncore [Member]
Product Information [Line Items]
Total revenue, net			17,087,965	2,147,654
Sale of Pharmaceutical Products Rx Compound and Peaks [Member] \| Core [Member]
Product Information [Line Items]
Total revenue, net			16,563,906	2,147,654
Shipping Income [Member] \| Noncore [Member]
Product Information [Line Items]
Total revenue, net			$ 524,059

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Sep. 30, 2024	Mar. 31, 2024
Product Information [Line Items]
Cash	$ 1,532,211	$ 697,721
Cash uninsured amount	$ 1,282,211	$ 266,090
Property and equipment useful life	5 years
Intangible assets useful life	5 years
Customers One [Member] \| Revenue Benchmark [Member] \| Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage	14.00%
Customers Two [Member] \| Revenue Benchmark [Member] \| Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage	12.00%
Customers Three [Member] \| Revenue Benchmark [Member] \| Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage	9.00%
Suppliers One [Member] \| Purchases [Member] \| Suppliers Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage	28.00%
Suppliers Two [Member] \| Purchases [Member] \| Suppliers Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage	12.00%
Suppliers Three [Member] \| Purchases [Member] \| Suppliers Concentration Risk [Member]
Product Information [Line Items]
Concentration risk, percentage	8.00%

Schedule of Effect of Restatement (Details) - USD ($)	3 Months Ended		6 Months Ended
Schedule of Effect of Restatement (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total Assets	$ 5,049,628	$ 3,079,613	$ 5,049,628	$ 3,079,613		$ 3,881,336
Stockholders’ Equity	3,201,132	1,971,909	3,201,132	1,971,909	$ 3,167,086	2,249,305	$ 1,527,328	$ 1,119,535
Accumulated deficit	(27,780,454)	(30,109,842)	(27,780,454)	(30,109,842)		$ (29,655,076)
Net Income	$ 798,368	444,581	$ 1,874,622	357,372
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total Assets		3,041,344		3,041,344
Stockholders’ Equity		1,933,640		1,933,640
Accumulated deficit		(30,148,111)		(30,148,111)
Net Income				354,872
Revision of Prior Period, Reclassification, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total Assets		38,269		38,269
Stockholders’ Equity		38,269		38,269
Accumulated deficit		$ 38,269		38,269
Net Income				$ (2,500)

Restatement (Details Narrative)	Sep. 30, 2023 USD ($)
Accounting Changes and Error Corrections [Abstract]
Goodwill, Gross	$ 138,312

Schedule of Inventory (Details) - USD ($)	Sep. 30, 2024	Mar. 31, 2024
Inventory Disclosure [Abstract]
Raw materials	$ 334,312	$ 266,776
Finished goods	97,905	48,962
Inventory	$ 432,217	$ 315,738

Inventory (Details Narrative) - Purchases [Member] - Suppliers Concentration Risk [Member]	6 Months Ended
	Sep. 30, 2024
Suppliers One [Member]
Product Information [Line Items]
Concentration risk percentage	28.00%
Suppliers Two [Member]
Product Information [Line Items]
Concentration risk percentage	12.00%
Suppliers Three [Member]
Product Information [Line Items]
Concentration risk percentage	8.00%

Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2024	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Equipment – cost	$ 280,197	$ 176,602
Less: Accumulated depreciation	(63,851)	(41,250)
Property and Equipment, Net	$ 216,346	$ 135,352

Property and Equipment (Details Narrative) - USD ($)	6 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 22,601	$ 14,370

Schedule of Supplemental Balance Sheet Related To Leases (Details) - USD ($)	Sep. 30, 2024	Mar. 31, 2024
Leases [Abstract]
Right of use asset, net	$ 219,627	$ 156,517
Operating lease liabilities
Current	118,227	70,487
Non-current	100,690	84,950
Total Lease Liabilities	$ 218,917	$ 155,437

Schedule of Lease Cost (Details) - USD ($)	6 Months Ended
Schedule of Lease Cost (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Depreciation	$ 37,184	$ 60,680
Interest on lease obligation	4,807	20,861
Total lease cost	$ 41,991	$ 81,541

Schedule Lease Term and Discount Rate (Details)	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Weighted average remaining lease term - Operating leases	2 years	2 years 9 months
Weighted average discount rate - Operating leases	3.00%	3.00%

Leases (Details Narrative) - USD ($)	Sep. 15, 2024	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Lease term year		2 years	2 years 9 months
Payments for rent	$ 4,078.12

Schedule of Intangible Assets (Details) - USD ($)	Sep. 30, 2024	Mar. 31, 2024
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (12,354)	$ (8,688)
Net Balance	29,775	28,441
Telemedicine Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	17,806	17,806
Web Properties [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross
Domain [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	24,323	19,323
Software [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross

Intangible Assets (Details Narrative) - USD ($)	6 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 3,666	$ 921

Schedule of Goodwill (Details) - USD ($)	Sep. 30, 2024	Mar. 31, 2024
Goodwill	$ 2,302,792	$ 2,302,792
Rx Compound Storecom LLC and Peaks Curative LLC [Member]
Goodwill	$ 2,302,792	$ 2,302,792

Goodwill (Details Narrative)	Nov. 08, 2022
Rx Compound Storecom LLC and Peaks Curative LLC [Member]
Restructuring Cost and Reserve [Line Items]
Acquired percentage	100.00%

Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)

Sep. 30, 2024

Mar. 31, 2024

Payables and Accruals [Abstract]

Accounts Payable

$ 392,227

$ 530,724

Accrued Expenses and other payable

^[1]

$ 1,158,238

$ 854,719

[1]	Accrued Expenses and other payable

Accounts Payable and Accrued Expenses (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Sep. 30, 2024	Mar. 31, 2024
Payables and Accruals [Abstract]
Employee-related Liabilities, Current	$ 838,000
Accrued Insurance, Current	72,000
Accrued Payroll Taxes, Current	81,000
[custom:MerchantFees]	93,000	$ 68,000
Credit card balance	$ 66,000
Accrued liabilities		$ 650,000

Schedule of Notes and Loans Payable (Details) - Equipment Finance [Member] - USD ($)	Sep. 30, 2024	Mar. 31, 2024
Short-Term Debt [Line Items]
Total debt	$ 79,114	$ 91,151
Current	30,592	30,592
Non- current	$ 48,522	$ 60,559

Related Party Balances and Transactions (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024
Related Party Transaction [Line Items]
Officers compensation	$ 2,679,308			$ 5,385,912
Stock repurchase	764,322	$ 922,795	$ 0
Avenvi LLC [Member]
Related Party Transaction [Line Items]
Stock repurchase	$ 115,303	273,776
Related Party [Member]
Related Party Transaction [Line Items]
Value of stock issued for services		$ 439,000

Stockholders’ Equity (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
Stockholders’ Equity (Details Narrative) - USD ($)	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued			0	0
Number of shares issued for debt settlements			0	0
Stock repurchase, shares			6,345,896	0
Value of shares repurchased		$ 764,322	$ 922,795	$ 0
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock repurchase, shares	11,545,898	(5,431,788)	(6,345,896)
Value of shares repurchased		$ 5,432	$ 6,346

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Oct. 01, 2024
Avenvi LLC [Member]
Subsequent Event [Line Items]
Business acquisition, description	On October 1, 2024, Earth Science Tech, Inc., a Florida corporation (the “Company”), completed the acquisition of Avenvi, LLC., (“Avenvi”), a Florida limited liability company owned by Giorgio R. Saumat, as an asset acquisition for a total of $1,058,788., with an initial payment of $258,788, followed by subsequent monthly payments of $200,000 for the next four months. The acquisition encompasses approximately four acres of vacant residential real estate intended for development, one commercial property comprising nearly half an acre featuring a standalone building with five thousand square feet, and cash or cash equivalents held by Avenvi. Visit: avenvi.com.
Mister Meds LLC [Member]
Subsequent Event [Line Items]
Business acquisition, description	On October 3, 2024, the Company completed the acquisition of Mister Meds, LLC, a Texas limited liability company, Owned by Mario G. Tabraue for fifty-four thousand two hundred dollars cash